Blog

New Tech-Driven Patient Activation Organization Combines Data, Behavioral Economics and Decision Science to Increase Speed and Reduce Costs

Launch of Hū Designed to Address Broad Clinical Trial Enrollment Challenges Heightened by COVID-19 Pandemic 

San Francisco, September 29, 2020 W2O today announced the creation of , the first-of-its kind Patient Activation Organization (PAO). Hū will usher in a new era of patient activism and engagement, resulting in access to better health and well-being. Hū’s unique approach combines data, behavioral economics and decision science to unlock drivers of human behavior – how people make decisions, what they value, what motivates them, what they fear and more – in order to give people a central role in every facet of the clinical trial experience.

An unprecedented decline in people’s willingness to participate in clinical trials threatens the development of new therapeutic, vaccine and device breakthroughs. In the past year, willingness to participate in clinical trials has plummeted from 85% to just 49%, according to Centerwatch. While technology and big data have changed the ease with which potential clinical trial participants are identified, until now, no one has used social and behavioral evidence to quantify the motivations that drive increased participation. Hū – short for hūman but long on humanity – is taking an approach that promises to bring a dramatic shift in participation rates, and the optimization of speed, cost and quality in research and development.

“We’re not bound by the way things have been done before, so we’re free to reimagine the potential of clinical trials and bring them to life in ways that will reshape how we think about, organize and conduct them,” said April Lewis, EVP and General Manager at Hū. “We’re at an inflection point where the consumerization of healthcare and the changes in attitude accelerated by COVID-19 demand that we take meaningful action to amplify the patient voice as a driver of R&D success. And we at Hū are uniquely positioned to affect change at scale.”

Hū is led by Jayson Dupré, D.O., M.B.A. Dr. Dupré joined W2O through the acquisition of 21GRAMS where he continues to serve as President. Recognizing the opportunity to leverage W2O’s proprietary analytics, insights, and creative to address challenges in clinical trial patient activation, Dr. Dupré tapped industry veteran, April Lewis, to be General Manager at Hū. With 20 years of success innovating and disrupting clinical trial operations across pharma and clinical research organizations, Lewis was part of the Quintiles/IMS executive merger team and Head of Trial Operations and Site Engagement Products at GSK.

The Hū vision has inspired leading experts from across the pharmaceutical sector to join the leadership team, including:

  • Jason Tse, EVP, Strategic Development, was previously with Pharma Intelligence where he was Head of Strategic Partnerships and M&A
  • Alexandra Charge, SVP, Offerings and Marketing, who was previously Global Head of Process and Enabling Solutions with AstraZeneca R&D
  • Ying Jiang, SVP, Delivery and Customer Success, who joined from IQVIA where she was Global Offerings Lead, Clinical Cost Benchmarking
  • Ronnie Du, SVP, Clinical Data and Offerings, who was previously Principal Data Scientist, Center for Design and Analytics at Amgen
  • Eric Roberts, VP, Trial Diversity & Inclusion, who was previously at Arnold Worldwide and a is career champion for multi-cultural communications
  • Alex McSherry, VP, Sales, was previously at IQVIA and Oracle where he led global business development efforts with major pharmaceutical clients

For more information on Hū, please visit www.WelcomeToHu.com and connect with us on LinkedIn.

A Revolution in Clinical Trials, an Evolution for W2O

Inspired by W2O’s analytics-driven, digital-first approach, Hū is the next step in W2O’s journey to use data and creativity to improve how healthcare is delivered, experienced and integrated into our daily lives. Clinical trials are a natural extension of W2O’s deep heritage of working from bench to bedside. W2O has been strategically broadening capabilities to become the clinical, commercial and corporate partner of choice to healthcare companies. The company’s growth is driven by the goal of advancing client needs in an increasingly virtual, social and digital reality, accelerated by the current pandemic.

“Forming Hū was a strategic choice, intended to speed up real, meaningful change in the clinical trial arena and is part of our own transformation into a global health innovation company,” said Jim Weiss, Founder and CEO of W2O. “Our vision has always been to make the world a healthier place by helping our clients make healthcare more accessible, equitable and beneficial to patients, providers and ultimately society. Hū gets us closer to that ideal.”

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com and connect with us on Twitter, LinkedIn and Facebook

# # #

Contact:

W2O

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Read More
Tags:

San Francisco and New York, September 24, 2020 W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, today announced it has acquired Elysia Group, a health economic and outcomes research (HEOR) consulting firm operating in the United States and Asia Pacific. Founded in 2014, Elysia provides pharmaceutical and medical device clients with innovative modeling approaches to health economic strategy and evidence development using data and analytics and real-world evidence.

Elysia Group will collaborate and integrate closely with Discern Health, which W2O recently acquired. Discern Health counsels leading healthcare organizations on the performance measures and innovative payment models that shape the market for their products and services.

“We are building our organization to help our clients stay ahead of the evolving healthcare policy, consumer and payor landscape,” said Rita Glaze, Practice Leader, Commercial Strategy and Market Access, at W2O. “The collective expertise and capabilities of Elysia and Discern enable us to help clients plan for and execute their commercial and market access strategies at greater quality and depth than ever before.”

Elysia Group Co-Founder and CEO Bruce Wang and Co-Founder and President Wesley Furnback have joined W2O as Health Economics and Real-World Evidence Practice Leaders reporting to Glaze. Together, these leaders will expand the firm’s offerings in economic modeling and real-world evidence with greater international reach and perspective.

“Joining W2O is a win-win,” said Wang. “Our value-focused capabilities combined with W2O’s data and technology platforms will be a true industry differentiator, adding more insights and value to our modeling and real-world data products. We look forward to leveraging our established relationships in the Asia Pacific market alongside W2O’s unique set of offerings and expanding the firm’s footprint in this important area.”

Prior to founding Elysia Group, Wang led the Health Economics & Outcomes Research group for Alliance Life Sciences as Vice President. He earned a Ph.D. in economics from the University of Washington and a B.A. in economics from Columbia University. Furnback served as a Senior Consultant at Alliance Life Sciences prior to founding Elysia Group. He received a Certificate in Health Economics & Outcomes Research from the University of Washington and earned a B.A. in economics from the University of Maryland, College Park.

“Our existing clients in the HEOR and market access space will benefit from the added services and solutions that W2O has to offer – all of which are based on data – from bench to bedside,” added Furnback. “Value-based care has never been more important, and we look forward to bringing our unique expertise to W2O’s unmatched roster of life sciences companies.”

W2O’s approach to growth is to add experts and capabilities that address client needs and recommendations. This is the seventh acquisition W2O has completed since the company announced its partnership with New Mountain Capital in 2019. This partnership and series of acquisitions continue to strengthen W2O’s offerings and further position the company as a go-to partner of choice to help clients accelerate clinical trials, achieve commercial success, and navigate and engage their stakeholders in an increasingly virtual, social and digital post-COVID-19 pandemic reality.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Read More
Tags:

Despite Pandemic Headwinds, Firm Heading Toward 50% Growth in 2020

San Francisco, September 16, 2020W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, announced today it has hired top talent from some of the world’s largest and most successful companies to continue its transformation into a global health innovation company.

“As healthcare becomes more personal, consumerized and digitized, W2O is firing on all cylinders – innovating and growing approximately 50 percent – in the face of unprecedented circumstances for our industry and the world,” said Jim Weiss, Founder and CEO of W2O. “The people who have joined us bring expertise, agility, leadership and relationships that will help our clients go further, faster, and ultimately achieve our vision of making the world a healthier place.”

W2O’s entrepreneurial spirit, 20-year track record of success, and vision for the future have attracted leaders from many of the world’s leading brands and organizations. These new hires are igniting solutions and providing strategic counsel to meet client business needs – now and in the future – helping W2O become the clinical, commercial and corporate partner of choice.

  • Julie Adrian – Global Chief Experience Officer
    • Adrian is integrating the best data-driven, creative and results-oriented approaches and bringing W2O’s customized capabilities and technologies together.
    • She is a 25-year veteran of the healthcare industry and inductee into the PharmaVoice100, with a background that includes agency leadership and in-house experience.
  • John Capodanno – President, Financial, Corporate & Capital Market Communications
    • Capodanno is growing W2O’s corporate communications and capital market offering to meet the evolving needs of life science companies.
    • He led the Healthcare & Life Sciences practice at FTI Consulting and drove one of the largest transactions in healthcare and a re-positioning of one of the industry’s largest R&D functions.
  • Nikki Levy – Practice Leader, Advocacy Relations
    • Levy is building a new practice to help clients create mutually beneficial relationships and ultimately achieve better patient outcomes.
    • She has more than 25 years of experience at companies through all stages of development including Genentech, Vertex, Alkermes and Wave Life Sciences, and was named to the PharmaVoice100 list.
  • David Magrini – President, CRM and Marketing Solutions
    • Magrini is building on W2O’s data and marketing technology foundations to develop performance marketing strategies and scalable CRM offerings to bring integration and measurable solutions to clients
    • He led the health practice for 10 years at Merkle, expanding its client base and growing it to become a Top 15 Healthcare Agency in the U.S.
  • Jane Petrino – Practice Leader, Communications Strategy
    • Petrino is leading a fast-growing team of integrated communication strategists.
    • She was the Managing Director of RXMOSAIC, where she led through double-digit growth for each of her years at the helm.

In a business based on people, W2O has also strengthened its human resources and talent acquisition teams with multiple leaders. Together, these leaders will retain, attract and build a diverse, equitable and inclusive workforce of the future for a new kind of health innovation company.

“Hiring, retaining and growing the best people is the foundation of our success. That’s the one constant in our ever-evolving business,” said Jennifer Gottlieb, Global President of W2O. “To do this, we are thinking completely differently about our people. We listen. And we use our own data to understand what motivates them, how to reward them, how to inspire them, and how to give them opportunities that go beyond what others offer. That’s what this dream team is doing.”

  • Marlena Edwards – Head of People and Performance
    • Edwards is ensuring our people can be their best and do their best work for clients.
    • She is a 15-year agency HR veteran, and was previously Chief Talent Officer at Huge, where she designed and drove talent strategies that fostered cultural connection, diversity and inclusion, productivity and retention.
  • Carrie Galli – Head of Organizational Growth and Planning
    • Galli is future-proofing how our people will succeed by improving how we work.
    • She joins from Golin Harris, where she served as Executive Vice President, Human Resources, implementing effective and innovative talent management practices.
  • Jonathan Robbins – Head of Talent Acquisition
    • Robbins is bringing the best people to W2O using tech-enabled and data-driven approaches.
    • He has successfully built, driven, led and delivered talent acquisition, engagement and development for organizations including Interbrand, frog design, IDEO, R/GA Nike and Microsoft.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com

Follow W2O on Twitter

Follow W2O on LinkedIn

Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Read More
Tags:

W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced findings from a research study on consumer attitudes toward data privacy, specifically personal health data.

The study, Consumer Attitudes on Health Care Data Uses and Privacy, was conducted in two waves – before and during the COVID-19 pandemic – to understand the overall perceptions of data privacy, gain insights into consumer awareness about data usage, and better understand consumers’ willingness to share health data. The study can be found here.

The findings indicate that before people will be confident in sharing their health data, they need education and information about how their data will be used. Consumers want control over their health data, including a permission-based system to share data, and the ability to opt out at any time. According to the survey, 70% of participants said they believed that health data should either not be shared or shared only with their permission.

Consumers also care most about the altruistic purposes of health data use. Nearly half of those surveyed indicated that they would only want their health data shared if they knew it would be used to improve healthcare outcomes for others. As a result, organizations should clearly outline how they are sharing and using health data, and how it can advance public health.

“Data is essential to driving progress and innovation in healthcare. The COVID-19 pandemic and interventions such as contact tracing and related technology applications have created an urgent need for companies to provide greater clarity around how health data is used,” said Dan Linton, Global Data Privacy Officer for W2O. “Consumers believe that their health data is private information and should be used to advance their health and public health in general. To achieve the advances possible to address COVID-19 and beyond, organizations must proactively consider and respond to these privacy concerns.”

The study was conducted as a 20-minute quantitative survey in September 2019 and a 25-minute online quantitative survey in May 2020 with more than 1,000 consumers who broadly represent the overall U.S. population. The findings indicate that consumers’ levels of concern over data privacy have increased since the pandemic began. Respondents in Wave 2 expressed more concern about their ability to keep their health data private compared to Wave 1, with 50% in the second wave extremely concerned versus 46% in the first wave.

Highlights of the survey findings include the following:

  • Data privacy, and particularly health data privacy, is crucial to consumer trust – 68% of respondents say that they factor in a company’s reputation for privacy protection when making decisions to engage with the organization.
  • Education about the critical need that health data can fulfill is a problem – The study showed that consumers are unclear about who may be collecting their health data or how it is being used. Unaided, 34% of respondents were aware of insurance companies collecting their health data, but only 5% identified health websites and applications.
  • Consumers want privacy protection and informed choice – 70% of respondents believe that health data should either not be shared or shared only with their permission.
  • Consumers are more likely to share health data for altruistic reasons– 44% indicated that they would only want their health data shared if they knew it would be used to improve healthcare outcomes for others. Only 24% of respondents believe data is collected to develop new therapies and only 29% believe it is being used to improve healthcare outcomes.
  • Fewer than 30% of Baby Boomers (ages 55 to 75), a group that might benefit most from COVID-19 interventions, indicated a willingness to download a COVID-19 contact tracing application compared with about 65% of Millennials (ages 25 to 39) and Generation Z (ages 18 to 24). Control, anonymity and the ability to delete data increased the likelihood that consumers surveyed would download the contact tracing app.

“This study is indicative of the need to continually gather the most valuable, data-driven insights to better inform strategies and solutions for improved health outcomes,” said Kevin Johnson, Group President and Managing Partner at W2O. “Understanding consumer attitudes and expectations is essential for organizations and leaders to adequately address such turbulent, transformative periods in the healthcare industry. As the implications of COVID-19 continue to unfold, these insights are more valuable than ever.”

Full results of the research study and an infographic can be found here.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved 18 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,400 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

Contacts

Sylvia Aranda, 424.201.9464
saranda@w2ogroup.com

Read More
Tags:

Sixth acquisition in just over a year deepens firm’s value, access and pricing insights, policy, communications, marketing and consulting capabilities

San Francisco and Baltimore, July 28, 2020 – W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, today announced the acquisition of Discern Health. This health economics and outcomes research (HEOR) consulting firm provides strategic direction and policy solutions to life sciences companies, government and nonprofit agencies, and health insurers.

Discern Health counsels leading healthcare organizations on the performance measures and innovative payment models that shape the market for their products and services. Discern Health also works closely with organizations to strengthen and quantify clinical and real-world evidence strategies that inform ongoing market access and commercialization initiatives. Discern Health’s staff previously held roles within leading organizations including the Centers for Medicare & Medicaid Services (CMS), the National Quality Forum (NQF), and the National Committee for Quality Assurance (NCQA). Discern has offices in Baltimore and Washington, D.C., further expanding W2O’s presence with now nearly 100 people dedicated to these increasingly important health policy arenas.

“Value-based care is a key driver of health system change,” said Guy D’Andrea, Founder and Managing Partner of Discern Health. “To be successful, health care companies need to integrate value-based strategy into each level of their organization and each stage of product development.”

“We’ve been working with W2O over the past year and have gotten to know each other well,” added Tom Valuck, M.D., J.D., Partner at Discern Health. “Being part of the W2O team means that we can supercharge our capabilities and incorporate world-class analytics and insights into our work, bringing even greater resources to our clients and, ultimately, improving patient outcomes.”

This is the sixth acquisition W2O has completed since the company announced its partnership with New Mountain Capital just over a year ago. W2O’s approach to growth is to add experts and capabilities that its clients recommend. This approach continues to strengthen W2O’s offerings and positions the company as a go-to partner of choice to help clients accelerate clinical trials, achieve commercial success, and navigate and engage all their stakeholders in an increasingly virtual, social and digital post-COVID-19 pandemic reality.

“Value-based metrics, the continued need for real-world data integration, and the changing landscape of federal, state and international health policy in the face of the COVID-19 crisis are impacting healthcare faster than ever before,” said Rita Glaze, Practice Leader, Commercial Strategy and Market Access at W2O. “Our clients need ongoing evidence-generation strategies that mirror the market dynamics they are facing, along with up-to-the-minute insights and counsel. This information is vital to guide policy positions and commercial decisions that will unlock maximum value for their products, solutions and services. With Discern Health as part of our organization, we will continue to raise the quality and depth of our data and analytics offering, to ensure it stands up to the scrutiny of peer and government review. We will truly be #BetterTogether.”

The Discern team will operate under W2O’s single, integrated profit and loss (P&L) operation, with access to all of W2O’s proprietary data models and tools as well as its 1,400 person strong multidisciplinary team – including data analysts, scientific strategists, branding experts, communications specialists and creatives – to build unfair advantage for clients and their brands. Additionally, the Discern leadership team will remain the same.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved 18 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,400 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Patrick Lynch, 516-574-3501

plynch@w2ogroup.com

Read More
Tags:

Former Havas Lynx Executive and President of the Health and Wellness Jury at Cannes will help firm create a global healthcare creative force

 New York, July 13, 2020 21GRAMS, a breakout healthcare firm and one of W2O’s operating firms, is doubling down on creativity with the appointment of Tom Richards as Co-Global Chief Creative Officer. In this role, Richards, who is based in the U.K., will serve as a creative partner to U.S.-based Frank Mazzola, one of the company’s founding members. Together, the vision is clear: Raise the value of healthcare brands and companies to be more relevant, meaningful and human.

Richards joins 21GRAMS from UK-based Havas Lynx, where he served as Chief Creative Officer. During his tenure, he grew the creative department to more than 100, led the company to win the Lions Health “Healthcare Agency of the Year” in 2018, and helped it become one of the UK’s top 10 creative agencies in 2019. Richards is also President of the Health and Wellness jury at Cannes, which he will lead in 2021.

“With an internationally recognized talent like Tom partnering with Frank, our reach and scope now extends globally,” said Robert Blink, Founder and CEO of 21GRAMS. “This shared role gives our clients two game-changing creative leaders who, together and across every account, regardless of geography, will oversee, elevate and push the creative work to places healthcare hasn’t been. Working collaboratively, they will strive toward their vision of raising the value of healthcare brands and companies to be more relevant, meaningful and human.”

21GRAMS’ advertising and marketing expertise in the healthcare sector coupled with W2O’s best-in-class data, analytics and insights provides organizations and brands with the knowledge and precision to build and nurture relationships among key stakeholders to drive business results. Acquired by W2O in January 2020, 21GRAMS broadens W2O’s advertising portfolio while elevating its overall offering with the most advanced data and analytics in the industry. The goal is to be “the first at what’s next in healthcare” by breaking down walls among PR, advertising, analytics and medical communications for a fully connected solution set that supports the rapidly changing needs of the healthcare industry.

“Ask any agency in health, around the world, who would be on their wish list,” said Co-Global Chief Creative Officer, Frank Mazzola. “9 out of 10 will say Tom Richards. The work he’s led consistently shows the industry what great looks like. Not just in ideas that break the norms of traditional advertising, but in craft. As someone who came up in copy, and Tom in art, we complement each other well. I’ve been a fan for years, so it’s an honor to partner alongside and see what we can do together. The goal is to open doors no one knew existed for the industry.”

“I have always admired 21GRAMS and its philosophy of finding what makes people tick, and creating work that really ‘gets’ them. Work that doesn’t just compete with other brands, but anything fighting for the audience’s attention,” said Richards. “It’s not every day you get to be a part of, and help build, a new kind of health agency – one with a passion for creativity at its heart and soul. The leadership team has great chemistry and delights in doing things differently, and I’m thrilled to be a part of it.”

About 21GRAMS

21GRAMS was built to be different by design, fusing advertising and education for the first time in an agency model. As two arms of the same body, these disciplines work seamlessly, to inject creativity into education and give advertising exclusive and personal access to doctors and patients – providing an unmatched ability to uncover deeper insights and create work that truly “gets” them. Using brands people love as a model for connecting with audiences, 21GRAMS adheres to the mantra “Medicine should be more inspiring than sneakers.” Obsessing less on minutia, and more on what makes people tick. For more information, visit 21GRAMSNY.com.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs more than 1,300 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

 

Read More
Tags:

San Francisco, June 22, 2020 – Jennifer Gottlieb, Global President of W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, has been named to the Board of Directors for the Muscular Dystrophy Association (MDA).

“I am honored to join MDA in its mission to improve the lives of people and families affected by neuromuscular diseases, especially given how vulnerable the population is during the current COVID-19 crisis,” said Gottlieb. “I look forward to bringing my deep healthcare experience to MDA to expand fundraising efforts and digital-enablement in support of innovations in science and care.”

MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases. Through innovations in science and care, MDA is creating more hope and answers for families living with muscular dystrophy and related diseases that take away physical strength and mobility. Research supported by MDA is directly linked to approved, life-changing therapies across multiple neuromuscular diseases. Additionally, MDA supports the largest network of multidisciplinary clinics providing best-in-class care at more than 150 of the nation’s top medical institutions. Each year, thousands of children and young adults with neuromuscular diseases learn vital life skills and gain independence at MDA’s summer camp and through recreational programs, at no cost to families.

“At this challenging time, we must remember that many diseases, especially neuromuscular diseases such as muscular dystrophy, spinal muscular atrophy, and ALS, urgently need innovations in research and care. MDA is an essential charity, and our patients are more vulnerable than ever. We are on the front-line delivering care to over 50,000 people and bringing critical education and resources to over 250,000,” said MDA President and CEO Lynn O’Connor Vos. “Jennifer’s passion, commitment and deep industry knowledge will help ensure that we increase our impact and continue to transform the lives of people affected by neuromuscular diseases, during this critical time and beyond.”

For more information about MDA, please visit its website at www.mda.org, or click here to access W2O’s “What2Know” podcast interview with O’Connor Vos.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs more than 1,300 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Read More
Tags:

Firm Also Receives Recognition in Multiple Categories

San Francisco, June 10, 2020 – W2O received multiple awards at the 2020 North American SABRE Awards, including “Large Agency of the Year” and “North American Agency of the Year.”  Considered the premier awards program for the PR industry, SABRE awards are given by PRovoke Media following an exhaustive research process involving more than 150 submissions and 50 face-to-face meetings with the best PR firms across the United States and Canada.

“Winning this year’s North American SABRE Awards is an immense source of pride and affirmation of the work we’re doing on behalf of clients to make the world a healthier place,” said Jim Weiss, Founder and CEO of W2O. “Our amazing group of professionals inspire me and each other with their relentless dedication to be the best. That attitude and behavior permeate our culture and partnership with clients, representing the foundation of our firm.”

In addition to winning the “Large Agency of the Year” and “North American Agency of the Year” categories, W2O was also recognized for the following achievements:

  • Placed second in the “Agency of the Decade” category.
  • Placed second in the “Best Large Agency to Work for” category.
  • Shared a first-place win with client Stallergenes Greer in the “Animal Health” category for “Augmenting Reality to Build an Engaging NAVDF Booth Experience for Vets.”

“Our 18 consecutive years of double-digit growth and success makes us the first agency to break into the large agency category in more than a decade,” said Jennifer Gottlieb, Global President of W2O. “These awards are further proof that our strategy of bringing the best people, purpose and creativity together with great healthcare clients continues to achieve extraordinary results.”

In addition to the SABRE awards, W2O was recently awarded more than 100 awards from several premier organizations, including:

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs more than 1,300 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773.343.3069

pduckler@w2ogroup.com

Read More
Tags:

Acquisitions, Organic Growth, Hiring Enables Firm to Partner with Clients Looking to Thrive in a Future-First Era with Deeper, More Expansive Technology and Scientific, Creative Offerings

Firm Adapts to New Normal by Offering Staff Flexibility, Mental Health and Childcare Support while Sheltering in Place

San Francisco, May 20, 2020 – W2O reported 2019 revenue increased by 26% to $223 million from $177 million in 2018 and improved operating profit. The company, which was recently recognized as a North American Agency of the Decade by PRovoke Media, has reported double-digit revenue growth since its inception in 2001. Growth was due to a combination of organic client expansion, new client partnerships, and the addition of new capabilities and offerings through hiring and acquisitions.

“Our growth this past year is even more remarkable because we achieved it while completing the sale of our firm, which resulted in an exciting partnership with New Mountain Capital,” said Founder and CEO Jim Weiss.  “Since then, we have completed five game-changing acquisitions and generated new and organic business growth, putting us on track to achieve over $300 million in revenue in 2020. We quickly adapted to a new normal and invested in our people so they can continue to deliver for their clients and their families while sheltering in place during this pandemic crisis. We are teaming up with clients and organizations focused on testing, tracking and new treatments to fight COVID-19 with everything they and we have got!”

Among the many initiatives W2O is supporting pro-bono are a COVID-19 news tracker with the California Life Sciences Association (CLSA) and the VentilatorSOS program with UC Berkeley.

Acquisitions

Five newly acquired firms have bolstered W2O’s science communications, medical education, creative, technology and digital capabilities and added more than 60 Ph.D. and M.D. staff members across the United States and Europe:

  • Arcus Medica: A deep bench of doctoral-level experts who specialize in translating complex clinical and scientific data into clear, meaningful content to help brands influence key audiences in today’s evolving healthcare environment
  • ISO.health: UK-based scientific and medical industry experts who create scientific educational programs for pharmaceutical, biotech and life sciences companies and organizations
  • Radius Digital Science: A scientific, digital, creative agency translating complex science into immersive, easy-to-understand creative experiences for healthcare brands
  • 21GRAMS: A rapidly growing, strategic and creative marketing, advertising and patient/medical education agency dedicated to making healthcare more human
  • Symplur: A social media analytics platform exclusively focused on the healthcare sector

W2O continues to build and expand its technology-based tools and platforms to provide real-time information, consumer sentiment and insights that inform highly tailored and results-oriented marketing communications approaches for its clients. In early 2020, W2O entered into a licensing agreement for access to HIPAA-compliant medical and pharmacy claims and electronic health record data. Coupled with the firm’s other non-traditional real-world data (RWD), W2O has new and unique views into the clinical landscape to help clients improve clinical decision-making, patient access and health outcomes.

Our People and Clients

Experts from across the technology, healthcare and marketing communications industries joined the firm in 2019, with more than 25 hires in leadership roles. Bringing leaders from diverse backgrounds complements the firm’s rich healthcare focus and drives new thinking for clients, bringing the best from multiple industries to the healthcare sector in an integrated fashion.  These leaders join W2O at a time when the focus on culture and employee engagement has never been stronger, as W2O has expanded wellness, mental health, childcare support and flexibility offerings for employees in response to the COVID-19 pandemic. The firm’s culture and experience has resulted in being recognized as a Best Agency to Work for by AdAge, MM&M, PRovoke, PRWeek and PRNews. W2O has also been shortlisted for Large Agency of the Year by MM&M, Medical Advertising News, PRWeek and PRovoke.

W2O partners with clients to create innovative work, using an integrated and data-driven approach to set clients apart from their competition and reach stakeholders in new, more personal ways. This work resulted in W2O winning more than 100 awards in 2019.

“The future is now with organizations being expected to lead and shape with purpose and meaning and maintaining relevance for greater innovation, connectivity and empowerment, added Weiss. “Driving this new ecosystem is a discover-based marketing and communications model allowing stakeholders to engage in real-time, accelerating learning, confidence and trust.”

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs more than 1,300 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 310-774-3425

pduckler@w2ogroup.com

Read More
Tags:

Accelerates Firm’s Evolution to Drive Consumerization and Digitization of Healthcare

San Francisco, May 4, 2020 – W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, announced today that Bryan Specht has been named Group President, Transformation, Consumer Activation and Marketing. In this role, he will expand W2O’s healthcare offering to include additional consumer-focused, tech-enabled and digital capabilities, accelerating its transformation to a digital healthcare firm.

With five acquisitions in the past seven months, W2O has been readying for further disruption and consumerization of healthcare, which has been accelerated by the COVID-19 pandemic. Specht will lead integration of people and technology across the firm, creating new ways to work with clients and potential partners to redefine how people experience healthcare and manage their personal health. A recognized transformation leader, Specht brings deep understanding of change management to accelerate W2O’s evolution.

“Current events are escalating the disruption and transformation happening in the healthcare industry, which is leveraging telemedicine, genomics and other data-based, digital experiences to improve people’s health and wellness,” said Jim Weiss, Founder and CEO of W2O. “Bryan understands the human side of healthcare and that patients expect real-time, personal and direct access to health information. As a firm, we have been on a journey to infuse the marketing principles of the consumer and influence world with science and healthcare to reach people in new ways, giving them more control to live healthier lives. Bryan will accelerate and dimensionalize these assets, resulting in a truly digital healthcare firm.”

Specht previously served as Chief Growth and Innovation Officer and was a key architect in launching ICF Next, a global consulting agency built through the convergence of 10 different award-winning marketing, engagement and digital businesses. Before ICF, Specht was president of Olson, overseeing the firm as it received a long list of industry honors including multiple agency of the year distinctions and more than a dozen Cannes Lions. A respected thought leader and change agent in the industry, he was three times named to PRWeek’s Power 50 List and was named to PRovoke’s Innovator 25.

“I am energized by the purpose, entrepreneurialism and incredible 18-year track record of double-digit growth at W2O,” said Specht. “Now is the time to harness W2O’s technology, data, creativity and marketing communications expertise to deliver some of the most important and meaningful engagement in the lives of people each and every day. As we’re witnessing with the current pandemic, W2O’s mission to make the world a healthier place through marketing communications has never been more important.”

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs nearly 1,400 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 310-774-3425

pduckler@w2ogroup.com

Read More
Tags:

Immediately Enhances Ability to Precisely Listen, Target and Engage with Key Influencers, Customers and Stakeholders —

— Firms Currently Collaborating to Track Critical COVID-19 Conversations —

San Francisco, Calif., April 14, 2020W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced the acquisition of Symplur, a social media analytics platform exclusively focused on the healthcare sector.

Symplur provides an easy-to-use interface and analytical capabilities that will help make W2O’s data and analytics operating system and technology accessible to a broader range of non-technical users. In the future, W2O will add new features and products to the platform that will further be informed by and benefit its wide range of healthcare clients.

Symplur’s proprietary, purpose-built social media analytics platform – the only tool of its kind on the market designed entirely for healthcare – allows for the rapid and easy identification of social media trends among physicians, patient advocates, life science professionals, media and other key audiences of interest to healthcare organizations, government entities and academic institutions. Through a collaboration with the California Life Sciences Association, W2O and Symplur are already utilizing the platform in conjunction with W2O’s proprietary data and technology stack to track COVID-19-specific conversations and trends across the healthcare ecosystem.

“Particularly in these challenging, uncertain times reverberating across global communities and economies, healthcare companies are looking to track essential information in an urgent and immediate manner utilizing data and analytics to discern insights for decision-making,” said W2O Founder and CEO Jim Weiss. “Symplur’s pioneering technology products turn up the volume on the most important, and often overlooked, voices in healthcare, ultimately engineering a path to a deeper understanding of this dynamic, complex sector. Symplur is another in a series of strategic investments in people, technology and platforms that we’ve made, and intend to make, to strengthen the solutions we provide to clients. W2O now has hundreds of people focused in technology, data science, audience analytics, activation and measurement and we will double down in this space going forward.”

The acquisition is designed to expand W2O’s proprietary data and technology platform and corresponding solutions, further enabling the firm to focus on combining data-rich intelligence with technology to solve clients’ problems in real-time, successfully communicate and market their product offerings, and drive overall value for their brands.

“Insights derived from social media analytics are significantly impacting the entire healthcare ecosystem. Our massive Healthcare Social Graph® platform, which uses machine learning, enables us to extract the most valuable insights to meet the needs of a diverse range of healthcare clients and ultimately drive their priorities forward,” said Audun Utengen, Symplur co-founder and CEO. “This work over many years has helped us expedite the development of relevant, powerful technology platforms like those used to help track critical COVID-19 conversations from authentic, expert sources.”

Symplur’s technology and intelligence reports are currently utilized by pharmaceutical companies and government agencies, including the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID).

Symplur and W2O are privately held companies, and the financial terms of the acquisitions are not being disclosed. This acquisition, which was completed in partnership with W2O’s private equity partner, New Mountain Capital, marks the firm’s fifth acquisition in nine months. Symplur, which will now operate as W2O symplur, adds a team of seasoned software architects and developers to the W2O family. Symplur co-founders Utengen and Thomas Lee will continue to serve in leadership roles and be key participants in the development of the firm’s audience planning product suite.

“Audun, Thomas and their highly adept team will strengthen our audience planning, intelligence and engagement capabilities while helping enrich our data taxonomy and making our technology platform and offerings more robust, automated, faster and easier to use,” added Adam Cossman, W2O’s Group President and Managing Partner, Technology Products & Solutions. “We look forward to developing additional end-to-end integrated marketing communications tools fueled by technology, taking what we already do for clients and increasingly automating it – turning our services into technology-driven solutions for which our clients are clamoring. To that end, we continue to look for innovative companies and technology that can enrich our offering in these critical areas.”

About Symplur

Headquartered in Pasadena, Calif., Symplur’s unmatched social media analytics platform tracks how physicians and other healthcare stakeholders produce and consume medical information online, which increasingly appears in free, open-access environments such as Twitter. Its proprietary Healthcare Social Graph®, the world’s largest database of its kind, comprises over tens of thousands of healthcare topics with billions of conversations around any given therapeutic area among millions of influencers in real-time. This unique platform empowers users to learn from the expertise shared publicly by patients, clinicians and other relevant stakeholders. Symplur’s additional solutions-oriented capabilities include influencer analyses, which utilize proprietary recursive algorithms to accurately identify the true influencers in any given healthcare topic; stakeholder segmentation, which identifies and categorizes the people behind the conversations; classification, which combines human curation and automated processes to organize, structure and appropriately categorize raw social data; and engagement analyses, which measure levels of engagement to determine what is resonating and driving conversations.

About W2O 

Founded by Jim Weiss in 2001, W2O seeks to make the world a healthier place through marketing communications. The Company applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business and organizational results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 310-774-3425

pduckler@w2ogroup.com

Read More
Tags:

Fast-growing Breakout Agency Brings Bold Creative and Deep Insights-Driven Approach to Global Healthcare Clients

SAN FRANCISCO & NEW YORK–(BUSINESS WIRE)–W2O, the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector, today announced the acquisition of 21GRAMS, a rapidly growing, strategic and creative marketing, advertising and patient/medical education agency dedicated to making healthcare more human.

The transformative acquisition will further strengthen W2O’s creative firepower and expand its capabilities in direct-to-consumer (DTC), direct-to-provider (DTP) and business-to-business (B2B) advertising and marketing to support the rapidly changing needs of the healthcare industry. 21GRAMS brings a differentiated method of fundamentally understanding a healthcare brand’s audience to ultimately make advertising less of an interruption and more worth their time, attention and action, while also offering a comprehensive suite of bold creative content capabilities. Together, W2O and 21GRAMS are committed to breaking down walls between the disciplines of advertising, marketing, communications and medical education to ensure a fully connected, inspiring and meaningful experience for patients, physicians and the entire healthcare ecosystem.

“21GRAMS is a true innovator, offering something different and more profound than its competitors. The agency’s philosophy that the work can and should tap into the human spirit, inspiring the invisible ‘something’ inside, aligns directly with our patient-first ethos and to what we are doing for clients. The unique strengths of 21GRAMS immediately enhances what we’ve been building over the last few years at W2O, a truly integrated approach to marketing communications. From my days as a client, I’ve always believed in the strength of a multi-disciplinary team spanning advertising, digital, branding, media activation and engagement working together in unison to deliver optimal business results,” said W2O Founder and CEO Jim Weiss. “Together, we will combine our experienced, results-oriented teams, integrating the best in proprietary data and analytics, creative content, and omnichannel activation to create a next-generation entity that’s equal parts technology and science – providing clients with a level of expertise that compares more to Netflix or Google than any network that currently exists. Simply put, we are joining together to be the first at ‘what’s next’ in health.”

This acquisition also bolsters W2O’s position in medical and scientific communications, as 21GRAMS has a robust medical and patient education division that will complement the three recent W2O acquisitions of Arcus MedicaISO.health and Radius Digital Science. This will allow for deeper engagement with healthcare influencers, which is critical to W2O’s bench to bedside approach. W2O works with more than 100 healthcare companies, from innovative start-ups to 24 of the 25 largest global pharmaceutical companies as well as some of the leading payors and providers.

“W2O has been leading the charge in health’s tech revolution, combining intelligence with the latest technology to provide an unfair advantage for brands and organizations – not at the speed our industry is accustomed to, but in real-time to elevate the overall value and relevance of healthcare marketing and communications in today’s chaotic, digital-first world,” said Robert Blink, Founder and CEO of 21GRAMS. “Joining this like-minded and forward-thinking organization gives us greater scale, as well as significant technological innovation and global reach – allowing us to match our ambitions to our abilities. Together, we are designing the future in health, connecting humanity and technology to position healthcare brands as more inspiring than sneakers, fast food or soda water.”

Over the last several years, W2O has significantly expanded and strengthened its overall portfolio, including its advertising and digital capabilities. Having curated a team of more than 200 of the industry’s leading professionals, W2O has been producing and executing innovative, award-winning marketing programs fueled by the organization’s proprietary data analytics platform. This approach measures success based on the impact it’s had on a client’s business performance. 21GRAMS adds more than 150 advertising and patient/medical education specialists to the W2O family. With extensive experience in working with healthcare brands across all major therapeutic areas and developmental stages, 21GRAMS’ core capabilities include advertising (direct-to-consumer and healthcare provider), patient storytelling, medical education, strategy, analytics and television production.

“Together, these powerful complementary forces put us in a more capable and competitive position than ever before to address the commercialization challenges and opportunities of our global clients,” added Weiss.

The 21GRAMS brand, approach and leadership team will operate under W2O’s single, integrated profit and loss (P&L) operation, with access to all of W2O’s proprietary data models and tools as well as it’s 1,000 person strong multidisciplinary team – including data analysts, scientific strategists, branding experts, communications specialists and creatives – to build unfair advantage for clients and their brands. Additionally, the 21GRAMS leadership team will remain the same with Robert Blink, Wendy LevineJayson Dupré and Frank Mazzola.

21GRAMS and W2O are privately held companies and the financial terms of the acquisitions are not being disclosed. A team from Excel Partners, led by Ed Soh and Doug Donohue, served as the exclusive financial advisor to 21GRAMS.

About 21GRAMS

21GRAMS was built to be different by design, fusing advertising and education for the first time in an agency model. As two arms of the same body, these disciplines work seamlessly, to inject creativity into education and give advertising exclusive and personal access to doctors and patients – providing an unmatched ability to uncover deeper insights and create work that truly “gets” them. Using brands people love as a model for connecting with audiences, 21GRAMS adheres to the mantra “Medicine should be more inspiring than sneakers.” Obsessing less on minutia, and more on what makes people tick. For more information, visit 21GRAMSNY.com.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

Contacts

W2O
Sylvia Aranda, 424-201-9464
saranda@w2ogroup.com

Read More
Tags:

SAN FRANCISCO – W2O, the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector, today announced that veteran biopharmaceutical executive Jonathan Peacock and distinguished advertising and digital marketing expert George Gallate have joined its board of directors. The appointments are intended to guide W2O’s accelerated growth plans to meet the evolving needs of its healthcare clients in a digital world and on an international scale.

Peacock has more than three decades of C-suite experience in the pharmaceutical, emerging biotech and corporate financial industries. He has held global chief financial officer (CFO) roles at Novartis and Amgen, as well as leadership positions in strategy and corporate finance at McKinsey & Company and PricewaterhouseCoopers. Gallate is rejoining the W2O board of directors. He has more than 30 years of experience in building and leading high-performing global and regional advertising and digital networks. As the former Global CEO and then Chairman of digital marketing agency giant Havas Digital, Gallate helped build the company into one of the largest digital networks globally.

“Jon and George are powerful additions to our board as we take our business to the next level to become a partner of choice for clients focused on becoming more relevant and competitive in a digital world,” said Jim Weiss, W2O Founder and CEO. “Jon has a proven track record of steering operations, strategy and business development for two of the world’s leading biopharmaceutical companies, and George has built one of the largest digital agency networks globally and guided agency alliances and partnerships with some of the world’s leading technology companies, such as Amazon and Google. Their respective insight and unmatched expertise will serve as a true asset and help guide us as we strategically build our talent pool and expand our capabilities to achieve our mission of making the world a healthier place through marketing and communications.”

During Peacock’s tenure at Amgen, the company’s share price increased by approximately 125%. While serving as CFO at Novartis Pharma, he helped increase the company’s operating profit by 40%. From 2014 to 2017, he served as Audit and Finance Committee Chair at Kite Pharma until its sale to Gilead for $11.9 billion in 2017. Following his time at Havas, Gallate served as the CEO of RKG, an independent search agency focused on the intersection of search and social, facilitating substantial revenue growth for the company throughout his tenure. He also negotiated the company’s sale to Merkle in 2014, where he then successfully served as Chief Marketing Officer for several years.

“W2O certainly lives up to its reputation of being one of, if not the most, diversified and dynamic healthcare marketing and communications firms in the industry. I continue to be impressed by the firm’s talent and use of analytics and technology to understand the evolving and ever-changing needs of healthcare companies,” said Peacock.

“As healthcare organizations and brands continue to look for new models to connect with patients, healthcare professionals and customers, W2O has distinguished itself as a premier firm when it comes to integrating analytics, creative, technology and activation skillsets into a unified delivery model that ultimately provides clients with the most high-value, breakthrough marketing and communications solutions,” said Gallate.

In June, W2O announced a new partnership with New Mountain Capital to drive growth and strengthen its relationship with clients throughout the healthcare spectrum. Since then, the company has made three acquisitions in the field of scientific and medical marketing communications and plans to pursue additional acquisitions to expand both its offerings and geographic presence.

The firm will continue to expand and enhance its board of directors, bringing in more diverse and differentiated expertise to expand its portfolio and talent.

About W2O 

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

Contact

W2O

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Read More
Tags:

SAN FRANCISCO AND MONTCLAIR, N.J. – W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced the acquisition of Radius Digital Science,  an award-winning scientific digital creative agency. Radius offers a differentiated service to the healthcare industry, fusing art and technology to translate complex science into immersive, easy-to-understand creative experiences for healthcare brands.

This acquisition is the latest in a series designed to expand and deepen W2O’s scientific marketing communications offering, which will organize and brand as W2O Science. Radius, which will now operate as W2O radius, adds nearly 25 scientifically trained, tech-savvy creative strategists to the W2O family.  Radius co-founders Michelle Peterson and Brandon Pletsch will serve in leadership roles within this business unit, which will be part of W2O’s single profit and loss (P&L) operation.

Combining Radius with W2O’s existing staff in this area along with that of recently acquired scientific communications and medical marketing firms ISO.health (now W2O iso) and Arcus Medica (now W2O arcus), W2O Science is now more than 100 people strong, including 18 doctoral level experts and 25 scientific creative strategists throughout the United States and Europe.

“We were already partnering successfully with Radius to bring our clients’ science to life through more dynamic and impactful digital media and evocative artistic expression,” said W2O Founder and CEO Jim Weiss. “Formally joining forces with this highly respected digital science powerhouse further diversifies our extensive ‘marketeching’ toolbox and raises the bar for how we execute on scientific creative across our suite of integrated capabilities.”

Headquartered in Montclair, N.J., Radius brings new science-based, digital creative capabilities to W2O, including medical illustration and 3D animation, molecular visualization, UX design and programming, experiential media, and creative execution for scientific congresses and tradeshows.

“In our experience of working closely with W2O, we’ve always been impressed with their ability to deliver highly targeted, impactful narratives, and the ability to tailor those messages to specific audiences,” said Pletsch, Partner, W2O radius. “Complementing that kind of industry insight with cutting edge, digitally-driven visual design that breaks down the complexities of the science is going to help us amplify a brand’s potential in ways we’ve never seen before.”

With experience across a broad range of disease categories and healthcare specialties, Radius has built a solid reputation among its client base as a solutions-oriented, strategic thought partner that can translate high-science into digestible, visually stimulating digital content. Whether it is building an iPad app that explains a disease, creating animations that show how a medical therapy works or producing a digital infographic that provides guidance for patients, the company has become a partner of choice for healthcare innovators looking to better position science as core to their relevance. Radius’ seasoned team will both complement and enhance W2O’s scientific and medical marketing communications offering and high-science advertising agency-of-record (AOR) platform.

“We are methodically evolving as a firm to achieve our vision to improve healthcare through marketing communications,” added Weiss. “We plan to do that by elegantly balancing the art and science these new firms bring to us and our clients. As our clients ask us to do more, we add the capabilities they expressly need and want. By integrating these specialized teams with our proprietary data analytics, already robust scientific strategy capabilities and integrated PR and advertising expertise, W2O places science at the epicenter of our offerings. This is all designed to strengthen the power, authenticity and differentiation of our clients’ narratives and build greater trust in their brands.”

Radius and W2O are privately held companies, and the financial terms of the acquisitions are not being disclosed. Nisivoccia, LLP, and Lum, Drasco & Positan, LLC acted as financial advisors to Radius in the transaction. 

About Radius Digital Science

Founded by Michelle Peterson and Brandon Pletsch in 2014, Radius Digital Science is a creative agency dedicated in equal measure to expert-level scientific strategy and visually-stunning, innovative digital experiences.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

Read More
Tags:

SAN FRANCISCO AND LONDON – W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced the acquisition of ISO.health, continuing its global expansion in scientific and medical marketing communications. ISO. comprises a talented team of industry experts who are adept at developing and delivering impactful omni-channel medical and scientific educational programs for pharmaceutical, biotech and life sciences companies and organizations.

“With healthcare brands having a predominantly international audience, the importance of leading with science is essential as it represents the backbone of a brand’s global narrative. ISO. is exceptionally capable at translating often highly complex data into insightful, effective language with relevant media and that reaches and resonates with multiple stakeholders across geographies,” said Jim Weiss, W2O founder and CEO. “This symbiotic partnership will enable us to provide more far-reaching support for our clients.”

ISO. brings a robust European-based scientific and medical communications arm to W2O, along with a well-established and synergistic client base. With extensive experience in working with healthcare companies across all major therapeutic areas and stages of development, ISO.’s core capabilities include strategic and operational planning, stakeholder mapping, opinion leader development, advisory board management, scientific narration, event conceptualization and management, disease awareness programming, data release planning and digital integration. The combination of ISO. and W2O will create a leader in scientific marketing communications on an increasing international scale, offering significant market growth opportunities in both Europe and the United States.

Last month, W2O acquired Philadelphia-based scientific and medical communications agency Arcus Medica (now W2O arcus) to bolster its growing high-science marketing communications discipline. The addition of ISO. to the W2O roster further cements W2O’s focus on placing science at the epicenter of its expansive marketing communications platform, ensuring the organization delivers the best integrated solutions that empower its clients throughout every stage of their lifecycle.

“Together we are building a global leader in analytics-driven medical and scientific marketing communications,” added Weiss.

ISO. will operate as W2O iso in W2O’s global brand architecture, with co-founders Suzanne Jacobs, Oli Burnham and Isabel Gibson serving in leadership roles within this business unit. The team will work together with additional multidisciplinary teams across the organization, harnessing science, strategy and innovation to deliver powerful results for clients.

“Since our company’s inception, our primary focus has centered on looking through the lens of healthcare professionals, patients and advocacy groups to develop holistic medical communications campaigns, rooted in science, that drive real value to our clients. W2O thrives on an analogous approach – giving brands a distinctive advantage by marketing science to deliver the most impactful stories,” said Jacobs, Partner, W2O iso. “We are thrilled to join this forward-thinking organization to create a next-level, geographically diverse offering that surpasses all expectations.”

ISO. and W2O are privately held companies, and the financial terms of the acquisitions are not being disclosed. Wright Vigar acted as exclusive financial advisor to ISO. in the transaction.

About ISO.health

Founded by Suzanne Jacobs, Oli Burnham and Isabel Gibson in 2016, ISO.health is a London-based medical communications agency with the belief that science makes the difference. It’s where cures come from and where value is created. It’s where we start. It’s what we love.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Read More
Tags:

W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced the acquisition of Arcus Medica. A recognized leader in medical and scientific communications, Arcus brings a deep bench of doctoral-level experts to W2O who specialize in translating complex clinical and scientific data into clear, meaningful content to help brands influence key audiences in today’s evolving healthcare environment.

This acquisition represents a vital move by W2O to disrupt the status quo in medical and scientific communications by creating a fully integrated communications agency that uses proprietary data and analytics to fuel scientific strategy, peer-to-peer medical engagement and patient-centered narration for clients. Given the highly complex and fragmented nature of the healthcare industry, companies and their brands require data-informed insights and clear, compelling storytelling to drive value. W2O and Arcus share a passion for uncovering deep scientific acuities to build best-in-class strategy and deliver high quality communications that resonate.

“Arcus is a trailblazer in the field of medical and scientific communications, consistently following the data to get to the right outcome for its clients. The addition of Arcus to the W2O family significantly enhances our medical and scientific communications expertise and enriches our offering in this key discipline,” said Jim Weiss, W2O founder and CEO. “Together, we will continue to place science at the center of everything we do, supplementing this prowess with unmatched data analytics and insights, robust strategy and creative know-how to ensure we deliver maximum impact to client business, from the bench to the bedside.”

With the integration of Arcus, W2O’s scientific and medical communications team will comprise approximately 40 best-in-class employees, including 16 doctoral level experts. Arcus co-founders Mary Seideman, MD, PhD, Stan Eapen, PharmD, and Jonathan Seideman, PhD, will all serve in leadership roles at W2O arcus, which will be an integral part of W2O’s single profit and loss (P&L) operation. These tenured industry experts, along with their seasoned team of communicators, will work closely with W2O’s scientific strategy team run by Ujwal Pyati, PhD, and other multidisciplinary teams across the company – including data analysts, brand strategists, creatives and media specialists – to drive differentiated communications and meet diverse client objectives.

“We founded Arcus on the premise of serving as strategic partners to our clients by providing world-class communications attuned to the unique challenges of the healthcare market. We couldn’t be more excited about our affiliation with W2O, given Jim and his team’s commitment to becoming the best by understanding every client’s business and treating it as its own, delivering the highest quality work and results and applying data analytics to every program it touches,” said Mary Seideman, Partner, W2O arcus. “Our partnership is genuinely symbiotic, and we look forward to working together to achieve something truly great for our dynamic clients and remarkable people.”

Earlier this year, W2O announced its partnership with New York based investment firm New Mountain Capital, enabling the company to support continued growth and accelerated scaling to meet the evolving needs of its clients in an increasingly digital and data-centric world. The partnership will take W2O to the next level of talent, capability, geographic and technology expansion to serve clients better and more expansively than ever while maintaining the independent, entrepreneurial spirit upon which the company was founded.

“At W2O we actively listen to our clients and continually enhance our capabilities based on what they ask for and what we foresee them needing to move their business forward,” Weiss added. “Integrating Arcus’ scientific and medical communications capability into our expansive, multidisciplinary service offering will ensure we are more competitively positioned and favored in the healthcare communications marketplace, ultimately enabling us to meet the changing demands of our clients and provide our people with greater career growth opportunities.”

Both companies are privately held, and the financial terms of the acquisition are not being disclosed. Delancey Street Partners acted as exclusive financial advisor to Arcus in the transaction.

About Arcus Medica

Arcus Medica prides itself on being strategic partners to its clients. The company’s deep scientific expertise in multiple disease areas allows for flawless delivery of world-class communications attuned to the unique challenges of today’s drug market. Arcus pairs extensive in-house industry experience with agency know-how to translate complex clinical and scientific data into clear and meaningful content.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

Read More
Tags:

San Francisco, June 12, 2019 – W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced that it has closed its previously announced investment partnership deal with New Mountain Capital.

“This partnership will allow us to achieve our mission of making the world a healthier place through marketing communications,” said Founder & CEO Jim Weiss. “We will invest to become the very best we can be, building our talent, technology and capabilities to serve our clients better and more expansively than ever – strategically, executionally, and geographically – all while maintaining our independent, entrepreneurial culture and spirit.”

About New Mountain Capital

New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, public equity, and credit funds with over $20 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit www.newmountaincapital.com.

About W2O 

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing services and communications to the healthcare sector.  W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Read More
Tags:

Company primed for next level of international, talent, capability and technology expansion to meet evolving needs of healthcare stakeholders in a digital world 

San Francisco, May 29, 2019 – W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced it has partnered with New Mountain Capital to accelerate continued growth and scale of the company to meet the evolving needs of its clients to most effectively and efficiently communicate with and influence their key stakeholders in an increasingly digital and mobile world.

The current W2O management team will remain in place, and both Jim Weiss, W2O Founder and CEO, and Jennifer Gottlieb, W2O President, will serve on the board of directors. The transaction is expected to close in the first half of W2O’s fiscal year 2019, subject to customary approvals and closing conditions. Current investment partner Mountaingate Capital is exiting W2O in the transaction. CG Petsky Prunier, part of the Canaccord Genuity Group, and Houlihan Lokey served as financial advisors to W2O and Mountaingate Capital. Financial terms were not disclosed.

In 2016, W2O partnered with Mountaingate to fund the firm’s strategic growth plans, which included three acquisitions – Pure Communications, Marketeching and Sentient – in addition to hiring key talent and making focused investments to expand and enhance its highly integrated technology and service offerings. Since that time, the firm’s revenues more than doubled from just under $100 million annually in 2016 with just over 400 people to anticipated revenues of more than $200 million in 2019 with nearly 800 people.

“We achieved in three years what we planned to do in five, so we were looking for a new partner that could help us maintain our momentum while preserving our dynamic, entrepreneurial culture that provides consistent career growth, innovation, and learning and development opportunities for our people,” said Weiss. “New Mountain is the right partner for this next inflection point in our evolution, one that aligns with an inflection point in healthcare as the sector continues to be impacted by technology at an unprecedented pace. Working with New Mountain, we will continue building and acquiring talent and companies with capabilities that clients have told us they need and want, and facilitate expansion in key markets overseas and in the U.S.”

“This partnership enables us to continue to control our own destiny and pursue our goal of ‘Becoming the Best’ for our clients, and to achieve a renewed mission to make the world a healthier place through marketing communications,” said Gottlieb. “There’s nothing more important than your health, and the future leaders in healthcare will be those that can communicate and compete most effectively in a mobile and digital world through both traditional and non-traditional media channels guided by next-generation analytics. We will not only continue to build and model our business to help our clients achieve this, but also become a digital health player in our own right.”

“W2O is a true leader in healthcare marketing, communications and analytics. We are excited to partner with Jim and his amazing team to support their next phase of growth as a key player in the evolution of the segment,” said Matt Holt, Managing Director at New Mountain Capital. “Healthcare is just beginning to discover new forces in medicine, prevention and cures, and W2O is participating with leading client organizations throughout the healthcare continuum. Our partnership is meant to support investments in key areas while enabling W2O to maintain its successful entrepreneurial culture, commitment to innovation, and unmatched client focus.”

According to Bruce Rogers, Managing Director of Mountaingate Capital, which initially partnered with W2O on this growth strategy, “W2O and its team exceeded our expectations in every way, successfully assimilating acquisitions, on-boarding talent and delivering data-driven insights to inform strategy and programming to achieve a competitive advantage for clients. This is a stellar team committed to client excellence, employee experience and development, and elevating the healthcare ecosystem. We are very pleased to see W2O advance to its next phase of growth with New Mountain Capital and wish Jim and the team the best for continued success.” 

Mountaingate Capital

Mountaingate Capital is a private equity firm based in Denver that specializes in building and empowering companies with strong growth potential and engaged leadership teams. Mountaingate’s focus on organic growth coupled with its proven customer-centric buy-and-build approach for add-on acquisitions and shared equity ownership with management creates more value for the end customer, while forging stronger, more collaborative, and more successful investment partnerships with management teams. Mountaingate targets investments in new platform companies typically with $5 million to $25 million of EBITDA. For more information on Mountaingate, please visit http://mountaingate.com.

About New Mountain Capital
New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, public equity, and credit funds with over $20 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit www.newmountaincapital.com.

About W2O 

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing services and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

 # # #

Contact:
W2O
Peter Duckler, 310-774-3425
pduckler@w2ogroup.com

Read More
Tags:

New York, April 11, 2019 – W2O Group, an innovative, analytics-driven, digital-first marketing and communications firm, today released its 2018 Relevance Index of Fortune 100 companies. Launched in 2017, the Relevance Index is a proprietary analytics model designed to determine the relevance of companies in multiple industries as it relates to stakeholder engagement in a social/digital reality. The Index tracks specific signals related to CEO approval, financial analyst coverage, employee visibility, search and the marketplace to determine the level of relevance for an organization or brand.

The 2018 Relevance Index found that Facebook, Google, Delta Airlines, Walt Disney, Apple, Costco and Amazon scored highest, mainly replicating their 2017 rankings. These companies displayed strong alignment of internal and external narratives, differentiating thought leadership, innovation-oriented cultures and agile interaction with key stakeholders. This year, Goldman Sachs and JP Morgan were new additions to the list.

The firm will also release its first-ever Healthcare Relevance Index in approximately two weeks.

“Relevance is the new reputation,” said Gary Grates, Principal at W2O. “It provides a more actionable measure for leaders to determine if they are truly connecting with key audiences – interests, concerns, beliefs, expectations – and if this connection is resulting in greater engagement with the organization. The Index not only captures relevance, it also illuminates what a company needs to do from a decision and action standpoint to help it achieve a bold and differentiating narrative.”

Following are key findings from the 2018 Relevance Index of leading Fortune companies, which is available in full at https://w2o.to/2018RelevanceIndex

A summary of the 2018 Relevance Index:

  • Only 8 percent of Fortune 100 companies registered a strong or resilient relevance.
  • 51 percent of companies registered as susceptible or weak, suggesting their relevance is highly vulnerable and they need to take significant, immediate, clear, genuine and sustained actions to engage with stakeholders who matter on the topics that matter to them.
  • Among the relevance leaders, drivers were positive recommendations from financial analysts, high CEO approval ratings, and high search interest (despite much lower news sharing).
  • Leaders:
    • Have a clear, consistent, differentiating narrative, POV, thought leadership are bold, nimble, attuned and ahead
    • Are Proactive:  bold statements and innovation-centric announcements drive relevance (see Goldman Sachs Crypto currency example on slide 10)
    • Understand the Trump factor:  responses to Trump statements (both critique and praise) are drivers of relevance
  • Companies that fall in the middle of the Index have low content sharing and low search interest, apathetic stakeholders, and incongruencies in internal and external scores (narratives, understanding, support, outlook, advocacy). Additionally, they experience challenges due to leadership changes, organizational flux or plateaus, and M&A activity.

“In 2018, we found it was easier for Fortune 100 companies to lose than gain relevance,” said Chuck Hemann, Managing Director, Analytics. “It’s critical that companies truly comprehend stakeholders in a deep manner as a foundation to engagement. Organizations can often lose sight of stakeholders in today’s fast-moving environment, missing the originality and impact needed to gain relevance. In 2018, eight of the top 15 relevance organizations were the same as 2017 albeit movement in terms of score. This indicates the fluidity of relevance and, for companies, necessitates a more disciplined effort to stay attuned and stay ahead.”

About W2O’s Relevance Index

Launched in 2017, W2O’s Relevance Index ranks the top Fortune 100 organizations on how they perform from an engagement and interaction standpoint. The Index tracks specific signals related to CEO approval, financial analyst coverage, employee visibility, search and the marketplace to determine the level of relevance for an organization or brand. The aggregate number provides a relevance score indicating where an organization or brand performs vis-à-vis its competitive set. The model reflects actual observed behavior vs. reported perceptions.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing services and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs nearly 800 people in 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

W2O

Peter Duckler, 310-774-3425

pduckler@w2ogroup.com

Read More
Tags:

Digital-first marketing and communications firm keeping ahead of curve by evolving capabilities, attracting and developing talent, and designing solutions for clients seeking unfair advantage

San Francisco, March 5, 2019 – W2O, an innovative, analytics-driven, digital-first marketing and communications firm, reported a 23 percent increase in revenue to $177 million in 2018 from $144 million in 2017. The company also increased its profit margin by a similar amount.

Since its founding in 2001 by healthcare communications executive Jim Weiss, W2O has distinguished itself by investing in the future specifically in the areas of data analytics and insights, digital and social media, content creation, and activation and strategic consulting. Over 150 of W2O’s clients actively use its analytics platform. This pioneering approach has set the firm apart and allows its hundreds of professionals to transcend traditional boundaries by connecting multiple components of the marketing, digital and communications mix. They weave this all together to partner with a growing roster of Fortune 500 clients, including 24 of the top 25 pharmaceutical companies, to create and deploy integrated solutions that measurably impact business results.

“In looking at 2018, the headline is this: Great Clients + Great People = Great Results,” said Founder and CEO Jim Weiss. “Putting all that aside, our results are a reflection of being strong partners with our clients – proactive in our thinking, responsive in our service, and strategic in our capabilities. We are always working hard to punch above our weight because we are on a mission to improve healthcare and the patient experience through strategic marketing and communications by achieving clarity, understanding and engagement.”

During 2018, the firm:

  • Launched the Relevance Health Index, an extension of its Relevance Model and Index covering the Fortune 500 and its engagement in a social/digital reality
  • Expanded its Market Access and Value & Pricing teams with the addition of new members and research offerings
  • Started our Scientific and Medical Communications group
  • Opened three new offices – in Atlanta, Washington, D.C. and Zurich
  • Supported 29 U.S. Food and Drug Administration product approvals
  • Designed, built and launched over 100+ corporate websites
  • Completed 2,200 analytics and research projects
  • Conducted 160+ executive and media coaching sessions, including with dozens of CEOs

The firm also strengthened its board of directors and senior leadership team with the addition of the following individuals:

  • George Gallate, W2O Board Member – formerly Chief Marketing Officer at Merkle, Global Chairman at Havas Worldwide Digital, and Regional CEO at Euro RSCG Asia Pacific
  • Deborah Hankin, Chief People Officer – a senior HR professional from a marketing and consultancy background with a diverse set of recruiting and talent development skills
  • Keri P. Mattox, Global Lead of Integrated Corporate Communications – formerly Vice President, Corporate & Investor Relations, at Amerisource Bergen, a Fortune 10 company
  • Hsiao Liu, Global Practice Leader – formerly Executive Vice President at Ogilvy Health and an integrated marketing leader focused on Asia Pacific market expansion

“It’s always been about delivering results for clients as they navigate their way through complex times. 2018 was another banner year for us with numerous new client wins across the pharma, biotech, payer/provider and digital health space, along with creating a larger, more integrated team across 15 offices,” said Jennifer Gottlieb, President of W2O. “In 2019, we will grow our global presence and mindset, invest in key expertise and portfolios, expand our PESO (paid, earned, shared and owned) media capability and offerings, extract insights from our ever-expanding and deepening data ingestion engine and combinatorial views from our qual and quant research approach, and hone operational efficiency, customer service and delivery.”

Additional notable accomplishments for W2O over the last 12 months include the following:

  • Won 150+ awards, including:
    • AdAge’s Best Places to Work 2019
    • The Holmes Report’s Best Agency to Work for 2018 (Large)
    • MM&M’s Best Places to Work 2018
    • MM&M and Holmes Report Large Agency of the Year (Finalist)
    • Jim Weiss was selected for the PharmaVOICE 100
    • Jennifer Gottlieb was inducted into the Hall of Femme 2018
    • Andy Boothe, Senior Director, Data Sciences, was named to the Holmes Report’s Innovator 25 list
  • Jim Weiss was appointed to the Healthcare Businesswomen’s Association (HBA) Global Board of Advisors
  • Angela Gillespie, President of W2O wcg, was appointed to the HBA’s 2019 Global Board of Directors and serves on the Executive Committee as secretary/treasurer
  • Entered its seventh year in partnership with Syracuse University for the W2O Center for Social Commerce at the Newhouse School, which is considered the premier industry-academic partnership model
  • Continued to invest in an innovative diversity healthcare communications effort with The LAGRANT Foundation. The partnership includes fellowships, in-office trainings and Jim Weiss’s seat on the LAGRANT board.
  • Served as lead sponsor of a Signature Research Study with IPR – The Future of Work – exploring technology, artificial intelligence (AI) and generational workforces on the state of organizational effectiveness
  • Rolled out Springboard, a leadership development program for W2O employees who are account director level and above and have been with the company for at least two years

“Every year since we began has been a year of transformation and learning,” added Weiss.

“We’ve never rested on our laurels and continually challenge ourselves and our clients to do better, to see what’s not in front of us, to dig deeper for the best approach, and to ignore labels and descriptions. It’s the W2O Way, and it won’t ever change.”

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing services and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs nearly 800 people in 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

W2O

Peter Duckler, 310-774-3425

pduckler@w2ogroup.com

Read More
Tags: